Literature DB >> 30511455

Warburg effect in Gynecologic cancers.

Yusuke Kobayashi1, Kouji Banno1, Haruko Kunitomi1, Takayuki Takahashi1, Takashi Takeda1, Kanako Nakamura1, Kosuke Tsuji1, Eiichiro Tominaga1, Daisuke Aoki1.   

Abstract

Mammalian cells produce energy by oxidative phosphorylation under aerobic conditions. However, in the 1920s, Otto Warburg reported the so-called "Warburg effect" in which cancer cells produce ATP that is biased toward glycolysis rather than mitochondrial oxidative phosphorylation not only in anaerobic environment but also in aerobic environment. Glucose is converted into lactate without going into mitochondria after being metabolized in glycolysis. Compared with oxidative phosphorylation, the glycolysis has a faster ATP production rate but it is very inefficient, resulting in cancer cells consuming a large amount of glucose. Increased glucose metabolism has become a biomarker for cancer cells and has led to the development of positron emission tomography with fluorodeoxyglucose. Till date, the Warburg effect has been an inefficient system for cancer cells with regard to efficient energy production, but since the consumption of oxygen can be suppressed as the tumor grows in mass, it is thought that the Warburg effect is advantageous in this situation wherein the tumor can increase despite the lack of vessels. In addition, an increased lactate by the glycolysis causes acidosis in the microenvironment of tissues, which is thought to damage the surrounding normal tissues and favor the invasion and metastasis of cancer. Thus, Warburg effect is one of the key mechanisms for cancer development and will be the next promising target. In this review, we introduce key players that can be targeted in the Warburg effect and outline the prospects of treatment, targeting the Warburg effect in gynecological cancer.
© 2018 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  Warburg effect; drug repositioning; glycolysis; oxidative phosphorylation; reverse Warburg effect

Mesh:

Year:  2018        PMID: 30511455     DOI: 10.1111/jog.13867

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  6 in total

1.  Predictive Value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Index on the Oncological Outcomes of Locally Advanced Cervical Cancer Patients.

Authors:  Kittinun Leetanaporn; Jitti Hanprasertpong
Journal:  Cancer Manag Res       Date:  2022-06-14       Impact factor: 3.602

2.  Correlation Between von Hippel-Lindau Gene Expression and Tumor SUVmax and Survival Prognosis in Hepatocellular Carcinoma.

Authors:  Gen Li; Yong Shen; Fengchao Wang; Sun Hong; Ming Cai
Journal:  Med Sci Monit       Date:  2020-02-20

3.  Glycolysis-Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma.

Authors:  Yan Zhang; Mingying Chen; Meihong Liu; Yingkun Xu; Guangzhen Wu
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

4.  ROCK2 Promotes Osteosarcoma Growth and Glycolysis by Up-Regulating HKII via Phospho-PI3K/AKT Signalling.

Authors:  Binbin Deng; Jianyong Deng; Xuan Yi; Yeqing Zou; Chen Li
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

5.  Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.

Authors:  Yusuke Kobayashi; Takashi Takeda; Haruko Kunitomi; Fumiko Chiwaki; Masayuki Komatsu; Shimpei Nagai; Yuya Nogami; Kosuke Tsuji; Kenta Masuda; Hideaki Ogiwara; Hiroki Sasaki; Kouji Banno; Daisuke Aoki
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-21

6.  Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma.

Authors:  Johannes Kliebhan; Andrej Besse; Kerstin Kampa-Schittenhelm; Marcus Schittenhelm; Christoph Driessen
Journal:  Clin Case Rep       Date:  2022-10-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.